Project Grant R01AR084827
Award Date
9/18/24
Completion Date
8/31/28
Dollars Obligated
$317K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), provides $228,218 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 12-week randomized controlled trial evaluating the serum urate-lowering effects of the SGLT2 inhibitor empagliflozin versus placebo in 60 gout patients with...
This $578,944 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The primary objective is to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The research aims to identify new and fine-map known genetic loci associated with OA and total joint replacement, disentangle OA heterogeneity by...
This federal Project Grant award, valued at $715,957 and awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA Program 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, supports research to elucidate the molecular mechanisms by which interferon cytokines promote the differentiation and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The award, with a project period from March 2025 to...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $361,300 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of North Carolina at Chapel Hill. The goal of this 2-year exploratory/developmental project is to use high-throughput small molecule screening and CRISPR screening technologies to identify signaling pathways and therapeutic targets for disease modification in osteoarthritis...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,657,392 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Pittsburgh. The grant funds research to repurpose FDA-approved drugs for the treatment of osteoarthritis (OA) using high-throughput screening in microphysiological models. The project aims to define the capacity of FDA-approved drugs to reverse cartilage-driven and inflammation-driven OA...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the role of reverse transendothelial migration of neutrophils in inflammation resolution. The $366,797 award, with a project period from Sep 24, 2024 to Aug 31, 2026, aims to provide new insights into the mechanisms by which certain inflammatory mediators,...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $196,460 to the University of Pittsburgh to test a novel microphysiological system as a tool to study neuroimmune interactions in osteoarthritis pain. The goal is to use this system, which includes cartilage, synovial-like, and innervated tissue, to investigate the influence...
This $143,949 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research aimed at defining how antibiotic-mediated gut dysbiosis and loss of certain short-chain fatty acid (SCFA)-producing bacteria alter intestinal and joint inflammatory responses. The 5-year project, led by Fang Roseanne Zhao, M.D., Ph.D. at Washington University, will use...